Evidence mapPaperPMID 40079806Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Systemic Immune-Inflammatory Index as a Prognostic Biomarker in Patients with Heart Failure: A Comprehensive Analysis.

Aihaidan Abudouwayiti, Yanxiao Li, Tumaresi Tuerxun, Muyashaer Abudurexiti, Dongqin Duan, Ying-Ying Zheng, Ailiman Mahemuti

Abstract read
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. LncRNA HOXA11-AS Promotes Myocardial Injury in Chronic Heart Failure by Sponging miR-342-3p.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aihaidan AbudouwayitiCardiovascular Department of The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.ORCID 0000-0002-3945-9973
Yanxiao LiThe First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China.
Tumaresi TuerxunCardiovascular Department of The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Muyashaer AbudurexitiCardiovascular Department of The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Dongqin DuanCardiovascular Department of The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.ORCID 0009-0005-1589-5921
Ying-Ying ZhengCardiovascular Department of The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.ORCID 0000-0001-5587-9911
Ailiman MahemutiCardiovascular Department of The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.ORCID 0000-0002-9174-5678

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectiveThis study aimed to assess the prognostic significance of the Systemic Immune-Inflammatory Index (SII) in chronic heart failure (CHF) patients and evaluate its potential as a predictive biomarker.MethodsA retrospective analysis was conducted on 2748 CHF patients from the First Affiliated Hospital of Xinjiang Medical University from 2012 to 2022. The primary outcome was all-cause mortality (ACM), with readmission rates as secondary endpoints. An optimal SII cutoff value of 916.68 was determined for predicting ACM.ResultsElevated SII levels were significantly correlated with an increased risk of ACM in CHF patients across all left ventricular ejection fraction (LVEF) categories. The high SII group had a 43.8% increased risk of ACM compared to the low SII group.ConclusionSII is a significant prognostic biomarker in CHF, independent of traditional risk factors, highlighting its importance in risk stratification and clinical decision-making, and necessitating further investigation in prospective studies.

Indexed as

Heart FailureInflammationAgedBiomarkersFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsBiomarkersall-cause mortalitychronic heart failureinflammatory biomarkersprognosissystemic immune-inflammatory index

Identifiers

PMID40079806
PMCPMC11907554

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.